FindTrial
Sign In

copper Cu 64-DOTA-trastuzumab

RADIATION5 trials

Sponsors

City of Hope Medical Center

Conditions

Adenocarcinoma of the Gastroesophageal JunctionAnatomic Stage IV Breast Cancer AJCC v8Bone MetastasesBreast CancerDiffuse Adenocarcinoma of the StomachHER2 Positive Breast CarcinomaHER2-positive Breast CancerIntestinal Adenocarcinoma of the Stomach

Phase 2

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
Active, not recruitingNCT02827877
City of Hope Medical CenterHER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer +1
Start: 2016-07-15End: 2026-09-25Updated: 2025-11-14

Phase 4

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
RecruitingNCT05376878
City of Hope Medical CenterAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
Start: 2022-12-21End: 2026-05-26Target: 10Updated: 2026-02-23

Unknown Phase

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
Active, not recruitingNCT01093612
City of Hope Medical CenterBreast Cancer, Stage IV Breast Cancer
Start: 2011-03-16End: 2026-09-08Updated: 2025-11-14
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
CompletedNCT01939275
City of Hope Medical CenterAdenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach +10
Start: 2014-11-19End: 2024-08-05Updated: 2025-02-28
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
Active, not recruitingNCT02226276
City of Hope Medical CenterBone Metastases, HER2-positive Breast Cancer, Liver Metastases +4
Start: 2015-01-07End: 2026-09-29Updated: 2026-02-13

Related Papers

64Cu-DOTA-trastuzumab PET/CT to predict response to ado-trastuzumab emtansine (TDM1) in HER2-positive metastatic breast cancer.
Journal of Clinical Oncology2017-05-20
Correlation of <sup>64</sup>Cu DOTA-trastuzumab positron emission tomography (PET) imaging with HER2 status by immunohistochemistry (IHC).
Journal of Clinical Oncology2014-05-201 citations